Screener
XPH vs BBH
State Street SPDR S&P Pharmaceuticals ETF vs VanEck Biotech ETF
Key differences
- Over the last 3 years, XPH has delivered higher annualized returns.
- XPH has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| XPH | BBH | |
|---|---|---|
| Annual cost (TER) | 0.35% | 0.35% |
| Fund size (AUM) | $355M | $365M |
| Since | 2006 | 2011 |
| Dividend yield | 0.65% | 0.52% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +46.3% | +26.8% |
| CAGR 3Y | +13.8% | +5.9% |
| CAGR 5Y | +4.5% | +1.2% |
| Sharpe 3Y | 0.57 | 0.21 |
| Volatility 1Y | 21.29% | 18.82% |
| Max drawdown | -35.96% | -39.86% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to XPH and BBH
Explore further